Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations

Recent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD) in parallel with the increase availability of novel therapy agents. In this review,...

Full description

Saved in:
Bibliographic Details
Published in:Hematology, Transfusion and Cell Therapy Transfusion and Cell Therapy, 2020-07, Vol.42 (3), p.269-274
Main Authors: Zalcberg, Ilana, D'Andrea, Mariana Gamma, Monteiro, Lucia, Pimenta, Glicínia, Xisto, Beth
Format: Article
Language:English
Subjects:
Chronic lymphocytic leukemia
DEL(17P) and TP53 mutations
Flow cytometry
MEDICINE, GENERAL & INTERNAL
Minimal residual disease
Mutational status of IGHV
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c560t-1c7bd2ba1837e6558b076cb204ebb3e0a9a66748ecc441f807fc2bb27366211b3
cites
container_end_page 274
container_issue 3
container_start_page 269
container_title Hematology, Transfusion and Cell Therapy
container_volume 42
creator Zalcberg, Ilana
D'Andrea, Mariana Gamma
Monteiro, Lucia
Pimenta, Glicínia
Xisto, Beth
description Recent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD) in parallel with the increase availability of novel therapy agents. In this review, the theoretical and practical aspects of response assessment have been discussed. These are based on updated recommendations of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) for genetic tests (TP53 mutation and IGHV status) and flow cytometry analysis for CLL. Methodological approaches and interpretation of results were also discussed. .
doi_str_mv 10.1016/j.htct.2019.07.006
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_scielo_journals_S2531_13792020000300269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S2531_13792020000300269</scielo_id><doaj_id>oai_doaj_org_article_4a9209aeed5a4ceaa6d9a8b6f265ef00</doaj_id><sourcerecordid>2320381664</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-1c7bd2ba1837e6558b076cb204ebb3e0a9a66748ecc441f807fc2bb27366211b3</originalsourceid><addsrcrecordid>eNpVkU2P0zAQhiMEYlfL_gEOyEcuDf6KnXBAQlWBSkVIC5ytsTNpXBK7OMlK_fe4dFmxvnjsmXln5pmieM1oyShT7w5lP7u55JQ1JdUlpepZcc0rwVZM1Pr5o62bq-J2mg6U0hybn_JlcSWYrqWk6ro4fV2G2bd-cv44-ADpRFoP-xCn2buJxI64PsXgHRlO47GP7jSfbVx-4ejhPdksKR4RArnDCSG5nmyDnz3M_h5JDGS925EV2dxt1yShi-OIoc3OGKZXxYsOhglvH-6b4uenzY_1l9Xu2-ft-uNu5SpF5xVz2rbcAquFRlVVtaVaOcupRGsFUmhAKS1rdE5K1tVUd45by7VQijNmxU2xvei2EQ7mmPyYhzQRvPn7EdPeQMpDDWgkNJw2gNhWIB0CqLaB2qqOqwo7SrNWedHKuHCI5hCXFHLz5vuZtjnj5RlzPiLjVk1O-HBJOC52xNZhmBMMT7p46gm-N_t4b7RkWlYyC7x9EEjx94LTbMa8KxwGCBiXyXDBqaiZUufQN__Xeizyb9niDxDvrgw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2320381664</pqid></control><display><type>article</type><title>Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations</title><source>SciELO Brazil</source><source>ScienceDirect Journals</source><source>PubMed Central</source><creator>Zalcberg, Ilana ; D'Andrea, Mariana Gamma ; Monteiro, Lucia ; Pimenta, Glicínia ; Xisto, Beth</creator><creatorcontrib>Zalcberg, Ilana ; D'Andrea, Mariana Gamma ; Monteiro, Lucia ; Pimenta, Glicínia ; Xisto, Beth</creatorcontrib><description>Recent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD) in parallel with the increase availability of novel therapy agents. In this review, the theoretical and practical aspects of response assessment have been discussed. These are based on updated recommendations of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) for genetic tests (TP53 mutation and IGHV status) and flow cytometry analysis for CLL. Methodological approaches and interpretation of results were also discussed. .</description><identifier>ISSN: 2531-1379</identifier><identifier>ISSN: 2531-1387</identifier><identifier>EISSN: 2531-1387</identifier><identifier>DOI: 10.1016/j.htct.2019.07.006</identifier><identifier>PMID: 31784406</identifier><language>eng</language><publisher>Brazil: Sociedade Brasileira de Hematologia e Hemoterapia</publisher><subject>Chronic lymphocytic leukemia ; DEL(17P) and TP53 mutations ; Flow cytometry ; MEDICINE, GENERAL &amp; INTERNAL ; Minimal residual disease ; Mutational status of IGHV ; Review</subject><ispartof>Hematology, Transfusion and Cell Therapy, 2020-07, Vol.42 (3), p.269-274</ispartof><rights>Copyright © 2019. Published by Elsevier Editora Ltda.</rights><rights>2019 Published by Elsevier Editora Ltda. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. 2019</rights><rights>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-1c7bd2ba1837e6558b076cb204ebb3e0a9a66748ecc441f807fc2bb27366211b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417454/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417454/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,24141,27915,27916,53782,53784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31784406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zalcberg, Ilana</creatorcontrib><creatorcontrib>D'Andrea, Mariana Gamma</creatorcontrib><creatorcontrib>Monteiro, Lucia</creatorcontrib><creatorcontrib>Pimenta, Glicínia</creatorcontrib><creatorcontrib>Xisto, Beth</creatorcontrib><title>Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations</title><title>Hematology, Transfusion and Cell Therapy</title><addtitle>Hematol Transfus Cell Ther</addtitle><description>Recent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD) in parallel with the increase availability of novel therapy agents. In this review, the theoretical and practical aspects of response assessment have been discussed. These are based on updated recommendations of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) for genetic tests (TP53 mutation and IGHV status) and flow cytometry analysis for CLL. Methodological approaches and interpretation of results were also discussed. .</description><subject>Chronic lymphocytic leukemia</subject><subject>DEL(17P) and TP53 mutations</subject><subject>Flow cytometry</subject><subject>MEDICINE, GENERAL &amp; INTERNAL</subject><subject>Minimal residual disease</subject><subject>Mutational status of IGHV</subject><subject>Review</subject><issn>2531-1379</issn><issn>2531-1387</issn><issn>2531-1387</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU2P0zAQhiMEYlfL_gEOyEcuDf6KnXBAQlWBSkVIC5ytsTNpXBK7OMlK_fe4dFmxvnjsmXln5pmieM1oyShT7w5lP7u55JQ1JdUlpepZcc0rwVZM1Pr5o62bq-J2mg6U0hybn_JlcSWYrqWk6ro4fV2G2bd-cv44-ADpRFoP-xCn2buJxI64PsXgHRlO47GP7jSfbVx-4ejhPdksKR4RArnDCSG5nmyDnz3M_h5JDGS925EV2dxt1yShi-OIoc3OGKZXxYsOhglvH-6b4uenzY_1l9Xu2-ft-uNu5SpF5xVz2rbcAquFRlVVtaVaOcupRGsFUmhAKS1rdE5K1tVUd45by7VQijNmxU2xvei2EQ7mmPyYhzQRvPn7EdPeQMpDDWgkNJw2gNhWIB0CqLaB2qqOqwo7SrNWedHKuHCI5hCXFHLz5vuZtjnj5RlzPiLjVk1O-HBJOC52xNZhmBMMT7p46gm-N_t4b7RkWlYyC7x9EEjx94LTbMa8KxwGCBiXyXDBqaiZUufQN__Xeizyb9niDxDvrgw</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Zalcberg, Ilana</creator><creator>D'Andrea, Mariana Gamma</creator><creator>Monteiro, Lucia</creator><creator>Pimenta, Glicínia</creator><creator>Xisto, Beth</creator><general>Sociedade Brasileira de Hematologia e Hemoterapia</general><general>Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)</general><general>Elsevier</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope><scope>GPN</scope><scope>DOA</scope></search><sort><creationdate>20200701</creationdate><title>Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations</title><author>Zalcberg, Ilana ; D'Andrea, Mariana Gamma ; Monteiro, Lucia ; Pimenta, Glicínia ; Xisto, Beth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-1c7bd2ba1837e6558b076cb204ebb3e0a9a66748ecc441f807fc2bb27366211b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chronic lymphocytic leukemia</topic><topic>DEL(17P) and TP53 mutations</topic><topic>Flow cytometry</topic><topic>MEDICINE, GENERAL &amp; INTERNAL</topic><topic>Minimal residual disease</topic><topic>Mutational status of IGHV</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zalcberg, Ilana</creatorcontrib><creatorcontrib>D'Andrea, Mariana Gamma</creatorcontrib><creatorcontrib>Monteiro, Lucia</creatorcontrib><creatorcontrib>Pimenta, Glicínia</creatorcontrib><creatorcontrib>Xisto, Beth</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SciELO</collection><collection>DOAJ: Directory of Open Access Journals</collection><jtitle>Hematology, Transfusion and Cell Therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zalcberg, Ilana</au><au>D'Andrea, Mariana Gamma</au><au>Monteiro, Lucia</au><au>Pimenta, Glicínia</au><au>Xisto, Beth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations</atitle><jtitle>Hematology, Transfusion and Cell Therapy</jtitle><addtitle>Hematol Transfus Cell Ther</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>42</volume><issue>3</issue><spage>269</spage><epage>274</epage><pages>269-274</pages><issn>2531-1379</issn><issn>2531-1387</issn><eissn>2531-1387</eissn><abstract>Recent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD) in parallel with the increase availability of novel therapy agents. In this review, the theoretical and practical aspects of response assessment have been discussed. These are based on updated recommendations of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) for genetic tests (TP53 mutation and IGHV status) and flow cytometry analysis for CLL. Methodological approaches and interpretation of results were also discussed. .</abstract><cop>Brazil</cop><pub>Sociedade Brasileira de Hematologia e Hemoterapia</pub><pmid>31784406</pmid><doi>10.1016/j.htct.2019.07.006</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2531-1379
ispartof Hematology, Transfusion and Cell Therapy, 2020-07, Vol.42 (3), p.269-274
issn 2531-1379
2531-1387
2531-1387
language eng
recordid cdi_scielo_journals_S2531_13792020000300269
source SciELO Brazil; ScienceDirect Journals; PubMed Central
subjects Chronic lymphocytic leukemia
DEL(17P) and TP53 mutations
Flow cytometry
MEDICINE, GENERAL & INTERNAL
Minimal residual disease
Mutational status of IGHV
Review
title Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A32%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multidisciplinary%20diagnostics%20of%20chronic%20lymphocytic%20leukemia:%20European%20Research%20Initiative%20on%20CLL%20-%20ERIC%20recommendations&rft.jtitle=Hematology,%20Transfusion%20and%20Cell%20Therapy&rft.au=Zalcberg,%20Ilana&rft.date=2020-07-01&rft.volume=42&rft.issue=3&rft.spage=269&rft.epage=274&rft.pages=269-274&rft.issn=2531-1379&rft.eissn=2531-1387&rft_id=info:doi/10.1016/j.htct.2019.07.006&rft_dat=%3Cproquest_doaj_%3E2320381664%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c560t-1c7bd2ba1837e6558b076cb204ebb3e0a9a66748ecc441f807fc2bb27366211b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2320381664&rft_id=info:pmid/31784406&rft_scielo_id=S2531_13792020000300269&rfr_iscdi=true